On the first day of trading | Nansen Technology (02261) debuted on the market with a 62.19% opening surge. The company is a supplier of intelligent driving line control brake solutions.
Nansen Technology (02261) has made its debut on the stock market. According to the announcement, the price per share is HKD 10.42, with a total of 57.5945 million shares issued, and each lot consists of 100 shares. The net proceeds are approximately HKD 533 million. As of this report, the stock has risen by 62.19% to HKD 16.9, with a trading volume of HKD 112 million.
Nascent Technology (02261) was officially listed, and the announcement shows that the price per share is HKD 10.42, with a total issuance of 57.5945 million shares and a lot size of 100 shares. The net proceeds amount to approximately HKD 533 million. As of the time of writing, the stock has risen by 62.19%, trading at HKD 16.9, with a transaction volume of HKD 112 million.
The prospectus reveals that Nascent Technology develops intelligent driving motion control technology and currently provides line control braking solutions. The company focuses on providing mission-critical line control braking solutions for intelligent driving, integrating fully self-developed control algorithms, software, and hardware.
According to information from ZhiShi Consulting, the company is: the first in China to apply electric control braking assistance solutions (NBS solutions) for commercial operations of Level 4 autonomous vehicles; the earliest Chinese company to supply self-developed electric control braking assistance solutions (NBS solutions) to leading domestic electric vehicle manufacturers; and by the 2025 sales volume of line control braking solutions, the second largest domestic independent third-party supplier of line control braking solutions.
Related Articles
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged nearly 6% as its net profit attributable to the parent company in the first half of the year is expected to increase more than fourfold. The two main business lines achieve a dual driving force.
The stock prices of Hong Kong-listed CXOs have risen collectively recently. After the profit warning, will MEDTIDE (03880) continue to decline against the market trend or bounce back from being oversold?
CMSC: The RAS track ushers in a genuine turning point, with a leap in core value in the field over the next three years.
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged nearly 6% as its net profit attributable to the parent company in the first half of the year is expected to increase more than fourfold. The two main business lines achieve a dual driving force.
The stock prices of Hong Kong-listed CXOs have risen collectively recently. After the profit warning, will MEDTIDE (03880) continue to decline against the market trend or bounce back from being oversold?
CMSC: The RAS track ushers in a genuine turning point, with a leap in core value in the field over the next three years.
RECOMMEND
